首页 | 本学科首页   官方微博 | 高级检索  
相似文献
 共查询到20条相似文献,搜索用时 140 毫秒
1.
纤溶酶在溶栓治疗中起重要作用,能够溶解血凝块的主要成分纤维蛋白。采用RACE方法从海蚯蚓消化道组织中扩增出海蚯蚓纤溶酶编码序列,构建该基因原核表达载体,并进一步构建工程菌表达融合蛋白,经Ni2+树脂柱纯化后通过平板法检测该融合蛋白纤维蛋白酶原激活活性。结果获得海蚯蚓纤溶酶的c DNA序列和氨基酸序列,并成功构建重组表达载体p ET-21a-AFE,表达纯化出融合蛋白,该融合蛋白能够激活纤维蛋白酶原而溶解纤维蛋白。总之,本研究获得了海蚯蚓纤溶酶的c DNA序列和氨基酸序列,并初步证明其具有纤维蛋白酶原激活活性,为临床新型溶栓药物的开发提供实验基础。  相似文献   

2.
《蛇志》2000,(2)
蕲蛇酶以全面改善纤溶系统各组份功能,诱导血管内皮细胞释放t-PA,t-PA将纤维蛋白溶酶原变成纤溶酶,溶解血栓。此外,本品分解血纤维蛋白原,生成降解A肽纤维蛋白单体,从而促进t-PA激活纤维蛋白溶酶原转变成纤溶酶效应,促进溶栓。蕲蛇酶是目前唯一对各种诱导剂引起的血小板聚集都具有明显抑制作用的药物。蕲蛇酶对新鲜性、陈旧性,及各种模型动静脉血栓均具溶栓作用蕲蛇酶溶栓和抗栓作用机理  相似文献   

3.
用PCR方法扩增人微小纤溶酶原(Microplasminogen,mplg)cDNA,与分泌型酵母表达载体pHIL-D8重组,构成受醇氧化酶基因(AOX1)的启动子与转录终止区控制的酵母表达质粒,然后转化GS115酵母菌,经表型筛选、PCR扩增筛选阳性克隆,然后以甲醇诱导表达,mplg分泌至培液,以酪蛋白-琼脂糖平板溶圈法、发色底物法检测,mplg显示出纤溶活性。  相似文献   

4.
为了实现外源蛋白在大肠杆菌中的可溶性表达,利用硫氧还蛋白作为分子伴侣构建双顺反子翻译偶联表达载体pDICT。将大肠杆菌硫氧还蛋白基因插入到pET22b载体NdeI和EcoR I位点之间,同时在硫氧还蛋白编码基因的终止密码子前加入核糖体结合位点,构建成双顺反子翻译偶联表达载体pDICT。将蚓激酶基因F238克隆到该载体,转化大肠杆菌BL21(DE3)并诱导表达。SDS-PAGE结果表明,所表达的蚓激酶F238是可溶性蛋白。利用血纤维蛋白法对表达产物进行活性测定,重组蚓激酶F238不仅具有纤溶酶活性,而且具有激活纤溶酶原的激酶活性。该双顺反子翻译偶联表达载体的构建,为在大肠杆菌中可溶性表达外源蛋白提供了新方法。  相似文献   

5.
依据已报道的地鳖虫成熟肽cDNA序列设计引物,通过RT-PCR法从地鳖虫(Eupolyphage sinensis Walker)中克隆得到675 bp地鳖虫纤溶活性蛋白 (fibrinolytic protein,EFP)成熟肽编码序列.将此片段克隆到表达载体pPICZα-A中,转化毕赤酵母GS115,甲醇诱导表达得到重组表达蛋白,经SDS-PAGE电泳和活性鉴定,表明重组EFP在毕赤酵母中均获得表达,重组表达蛋白相对分子质量为28.2 kD,表达产物分子质量与理论分子质量相符.重组蛋白在毕赤酵母中以分泌形式表达,具有纤溶活性.  相似文献   

6.
利用生物信息学手段,以期获得蚯蚓纤溶酶F-Ⅰ-0组分的基因。根据从粉正蚓(Lumbricus rubellus)中分离的FⅠ0组分的N端氨基酸序列VVGGSDTTIGQYPHQL,利用DNAMAN软件通过电子克隆方法,从Lumbricidae 的dbEST中获得该组分的核酸序列信息,设计特异引物, 经过RT-PCR,成功地从赤子爱胜蚓(Eisenia foetida)中克隆到一条蚯蚓纤溶酶新基因,命名为EfP-0。EfP-0基因全长678bp, 编码225个氨基酸的成熟肽,属丝氨酸蛋白酶,胰蛋白酶家族,与F-Ⅰ-0组分的氨基酸组成非常接近。BLAST证明,EfP-0与已报道的蚯蚓纤溶酶基因之间的相似性均低于40%,因此为蚯蚓纤溶酶中的一个新基因,GenBank 登录号为DQ836917。构建的pMAL-c2x-EfP-0重组质粒,在大肠杆菌TB1中获得融合蛋白MBP-EfP-0的可溶性表达,表达产物有酪蛋白平板溶解活性。  相似文献   

7.
摘要 Alfimeprase(ALF)是蛇毒纤溶酶Fibrolase的N端突变体,有纤溶活性而无出血活性。通过双酶切从克隆载体上获取目的基因alf,并将其克隆至毕赤酵母分泌型表达载体pPICZα A,经高效电转化、Zeocin筛选鉴定及培养条件pH、每天甲醇流加终浓度、菌体生长密度和甲醇诱导时间的优化,获得了重组ALF(rALF)高表达菌株pPICZ? A-alf / GS115,且在优化条件下rALF的最高产量达425 mg/L。通过His•bind柱纯化后,rALF纯度高达95 %,SDS-PAGE和Western blot分析表明rALF的分子量约为24 kDa,且能与一抗特异结合。纤维蛋白平板法纤溶活性鉴定结果进一步说明rALF获得了高活性分泌表达。这即为ALF的深入研究和工业化生产应用奠定了重要基础。  相似文献   

8.
血管生长抑制因子Kringle 5 是目前发现的抑制血管内皮细胞增殖和肿瘤生长的活性最强的纤溶酶原片段,特异性高而毒副作用小,在肿瘤的治疗方面具有潜在的巨大价值和广阔的应用前景。根据K5基因的序列设计PCR引物,通过PCR从已有的克隆载体扩增出人纤维蛋白溶酶原的K5部分基因,将K5基因克隆入原核表达载体pET15b,经序列测定,成功构建了pET15b-K5非融合表达载体。将重组载体导入大肠杆菌中IPTG诱导表达,SDS-PAGE分析目的蛋白主要以可溶形式存在于菌体中,破碎后上清通过阳离子交换层析,纯化获得纯度大于95%的目标蛋白,脱盐后对分子量测定推测形成了三聚体。通过鸡胚绒毛尿囊膜法证明蛋白产物对鸡胚绒毛尿囊膜血管增生有一定的抑制作用。  相似文献   

9.
采用 DNA重组技术构建了表达鼠抗人纤维蛋白单链抗体与低分子量尿激酶融合基因的真核表达载体。通过磷酸钙共沉淀法 ,将该表达载体转染到中国仓鼠卵巢细胞二氢叶酸还原酶基因缺陷株 ( CHO- dhfr-)中 ,利用选择培养基筛选出稳定表达的细胞株 ,溶解圈法测定融合蛋白的表达水平为每 1 0 6细胞每天 5 8IU。该融合蛋白保留了与纤维蛋白的结合活性和溶解纤维蛋白的溶纤活性。SDS- PAGE,Western印迹法分析证明融合蛋白的相对分子质量约为 70× 1 0 3  相似文献   

10.
通过PCR的方法从Bacillus subtilis基因组中克隆了中性植酸酶基因nphy,DNA全序列分析表明其结构基因全长1152个核苷酸(编码383个氨基酸),5′端有一编码26个氨基酸的信号肽序列。去除信号肽编码序列的nphy克隆到大肠杆菌IPTG诱导表达载体pTYB40上,在大肠杆菌中得到了高效表达,表达量达到大肠杆菌可溶性蛋白的40%以上,表达产物具有生物学活性,证实了克隆到的中性植酸酶的编码基因有正常的生物学功能。  相似文献   

11.
新型水蛭素嵌合抗栓剂的构建表达与功能研究   总被引:1,自引:0,他引:1  
水蛭素(Hirudin,HV)作为新一代抗凝剂,它是目前已知最强的天然凝血酶抑制剂,并有望在临床上完全取代肝素。虽然水蛭素有许多优点,但出血倾向是其在临床应用上的主要副作用。目前尚没有好的解决办法。针对水蛭素在临床应用中所出现的这个问题,依据血栓形成的生理生化机制,构建出了含FXa识别序列水蛭素嵌合抗栓剂,来降低水蛭素在非血栓部位的活性从而减小出血的危险。小鼠尾部血栓模型实验表明:此新型嵌合抗栓剂能在不减少水蛭素抗凝血活性的同时,又能大幅度地降低出血副作用。具有非常重要的临床意义。  相似文献   

12.
重组葡激酶和水蛭素融合蛋白的血栓靶向性机制   总被引:1,自引:0,他引:1  
为解释以凝血因子Xa(FXa)的识别序列为连接肽的葡激酶和水蛭素的融合蛋白(命名为SFH)在体内的强溶栓和低出血的特征,研究分析了SFH的两个血栓靶向性作用机理.首先采用ELISA和免疫组化的方法在体外分析了由水蛭素游离的C末端赋予的SFH对血栓的靶向性,结果显示SFH对凝血酶和富含凝血酶的血栓具有更高的亲和力.为阐明SFH抗凝活性在血栓部位的靶向性释放,构建表达了仅在水蛭素N末端连接FXa识别序列的水蛭素衍生物(命名为FH).体外试验结果表明完整的FH无抗凝活性,在体内FH可以发挥抗栓作用,且出血副作用较低,这些结果说明FXa的识别序列可以封闭水蛭素的抗凝活性,在体内FH可以由于FXa的成功裂解而释放其抗凝活性,且其抗凝活性可能仅局限于血栓局部.这就间接说明了SFH的抗凝活性可以在血栓局部进行靶向性释放.以上两个血栓靶向性作用机理是SFH在体内发挥更高溶栓效率和降低出血副作用的重要机制.  相似文献   

13.
用化学合成的方法合成了水蛭素12肽基因的编码序列,通过DNA重组技术将水蛭素12肽基因片段与低分子量单链尿激酶cDNA片段连接构建了融合基因。融合基因在大肠杆菌中获得表达。体外实验结果表明,表达的融合蛋白具有溶纤活性和抗凝活性。  相似文献   

14.
A recombinant gene for BPTI (bovine pancreatic trypsin inhibitor) is expressed in Escherichia coli using a MBP (maltose-binding protein) fusion vector. BPTI is fused through an FXa (blood coagulation factor Xa protease) target sequence (Ile-Glu-Gly-Arg) to the C-terminus of MBP. The MBP moiety of the hybrid protein enables purification in one step utilizing MBP's affinity to cross-linked amylose, and the FXa target sequence allows specific cleavage of the hybrid protein. Effective FXa cleavage is achieved by spacing the FXa target sequence and Arg-1 of the BPTI sequence with four residues (Met-Glu-Ala-Glu). The resulting N-terminal extended BPTI is readily converted to the wild-type sequence by trimming with cathepsin C exopeptidase, for the activity of which the spacing tetrapeptide is optimized. FXa cleavage is prohibited when the target sequence is placed next to Arg-1. In this construction, off-target cleavage at a somewhat homologous sequence (Val-Pro-Gly-Arg) results in five- or six-residue extended BPTI, indicating new details of the FXa specificity. The yield of highly purified recombinant BPTI is 3-6 mg/liter of culture, making the MBP-BPTI expression system convenient for the production of sufficient amounts of protein for NMR studies. 1H NMR is used to analyze the N-extended BPTI analogues.  相似文献   

15.
EH蛋白是一种水蛭素衍生物,它是在水蛭素的N端引入了一小段寡肽,该寡肽可被凝血因子XIa(factor XIa,FXIa)和Xa(factor Xa,FXa)裂解释放水蛭素的抗凝血酶活性.比较在不同条件下FXa裂解EH蛋白的效果,包括裂解时间(2h,4h,6h,8h,10h,20h)、裂解温度(25℃,37℃,40℃)...  相似文献   

16.
Gao J  Hu Z  Zhao Z  Liu G  Ren Y  Chen G 《The protein journal》2011,30(8):521-528
In the present study, we designed a novel targeted multi-functional fusion protein LHAD composed of LL-37, FXa recognition peptide, hirudin-12-residue, AAP, and RGD peptide. It was expressed in the Pichia pastoris GS115 strain and purified by affinity chromatography. The in vitro studies suggested that the novel designed protein exhibited antibacterial activity, anti-platelet aggregation and anti-thrombin activities. Moreover, the capability of anti-thrombin was significantly increased compared to that of natural hirudin. Our study may provide a potential approach to design multi-functional drugs for the prevention and management of thrombosis.  相似文献   

17.
Many recombinant proteins are synthesized as fusion proteins containing affinity tags to aid in the downstream processing. After purification, the affinity tag is often removed by using a site-specific protease such as factor Xa (FXa). However, the use of FXa is limited by its expense and availability from plasma. To develop a recombinant source of FXa, we have expressed two novel forms of FXa using baby hamster kidney (BHK) cells as host and the expression vector pNUT. The chimeric protein FIIFX consisted of the prepropeptide and the Gla domain of prothrombin linked to the activation peptide and protease region of FXa, together with a cellulose-binding domain (CBD(Cex)) as an affinity tag. A second variant consisted of the transferrin signal peptide linked to the second epidermal growth factor-like domain and the catalytic domain of FX and a polyhistidine tag. Both FX variants were secreted into the medium, their affinity tags were functional, and following activation, both retained FXa-specific proteolytic activity. However, the yield of the FIIFX-CBD(Cex) fusion protein was 10-fold higher than that of FX-CBD(Cex) and other forms of recombinant FX reported to date. The FXa derivatives were used to cleave two different fusion proteins, including a biologically inactive alpha-factor-hirudin fusion protein secreted by Saccharomyces cerevisiae. After cleavage, the released hirudin demonstrated biological activity in a thrombin inhibition assay, suggesting that this method may be applicable to the production of toxic or unstable proteins. The availability of novel FX derivatives linked to different affinity tags allows the development of a versatile system for processing fusion proteins in vitro.  相似文献   

18.
EK (enterokinase) is a serine proteinase which consistsof a heavy chain and a light chain linked by a disulfidebond. The light chain of EK contains a chymotrypsin-likeserine proteinase domain sufficient for the normal recog-nition and cleavage of EK subst…  相似文献   

19.
Staphylokinase (SAK) is an effective thrombolysis agent for therapy of myocardial infarction. We have constructed a fusion SAK variant (SAK-HV) with a thrombin-binding domain composed of 12 amino acids from hirudin and expressed it in Escherichia coli and purified the resultant protein. SAK-HV maintained fibrinolytic activity similar to SAK and had anticoagulant activity attributable to its hirudin segment. Measurement of thrombin-binding activity in vitro demonstrated that SAK-HV possessed binding activity with thrombin while SAK did not. SAK-HV might thus be a more potent thrombolytic agent with anticoagulation property than SAK.  相似文献   

20.
Using a phage library, seven peptide sequences with high affinity to human microplasminogen were obtained. Caseinolytic assay indicated that only the synthesized peptide P07 had slight fibrinolytic activity. To enhance its plasminogen activation ability, peptide P07 was fused into loop 32-35 of hirudin. In vitro assay demonstrated that this hirudin-like fusion protein can activate human plasminogen and retain the function of thrombin inhibition. Fusing the sequence "SPDASRL" into hirudin generated a plasminogen activation activity 100 times higher than peptide P07 in chromogenic and radial caseinolytic assay. This significant functional improvement might originate from a more specific active structure due to the hirudin scaffold.  相似文献   

设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号